A study published in the Annals of Oncology has analyzed data on young patients with acute lymphoblastic leukemia (ALL) to evaluate risk factors for febrile neutropenia and infection-related complications.
A study published in the Annals of Oncology has analyzed data on young patients with acute lymphoblastic leukemia (ALL) to evaluate risk factors for febrile neutropenia and infection-related complications.
Of the 2420 infection episodes seen in 409 children undergoing treatment for ALL, febrile neutropenia was seen in 1107 cases. The study found higher rates of neutropenia among patients with certain risk factor characteristics. A patient’s risk of neutropenia or infection also varied based on the stage of therapy, from the initial induction phase to the continuation phase.
Factors determining a patient’s risk group (low, standard, or high-risk) include age at diagnosis, initial white blood cell count, spread to other organs, and response to treatment. Clinicians use these risk groups to determine the intensity of treatment. Standard- and high-risk patients received more intensive therapy during the early continuation phase and had more incidences of neutropenia compared with low-risk patients. Age between 1 and 9.9 years at diagnosis was associated with febrile neutropenia in both the induction and later continuation phases of treatment. More intensive chemotherapy was also associated with higher rates of neutropenia.
The study also examined patient risk factors for infection-related complications. The most common type of infection among the 1313 episodes was upper respiratory, followed by ear, bloodstream, and gastrointestinal infections. Infections were most frequent during the induction or reinduction stages when patients undergo the most intensive chemotherapy treatment, but respiratory and ear infections were also seen during continuation phases.
The standard- and high-risk patients receiving more intensive therapy had higher incidences of infections. Age between 1 and 9.9 years at diagnosis was associated with infections during the later continuation phase of treatment. White race was associated with infection during the induction phase of treatment. A lack of neutrophil surge after dexamethasone treatment was associated with infections, as it can reflect the poor bone marrow reserve.
The study authors recommend that clinicians closely monitor children with these risk factors so they can be treated with antibiotics at the first sign of infection. Modifications to the chemotherapy regimen should also be considered for these at-risk patients.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More